PharmAbcine Inc. has entered into a research collaboration with Wuxi Shuangliang Biotechnology (SLBio) to evaluate the combination of each party’s clinical candidate, olinvacimab and C-005, in treating non-small cell lung cancer (NSCLC). NSCLC is the leading cause of cancer-related deaths in the US and China.   Olinvacimab, the leading clinical candidate being developed by PharmAbcine, is currently in a phase II clinical trial in Australia and USA in bevacizumab non responding rGBM patient...